
Supplementary Material

Table S1. MRD/ Flow status at MRD level and response according to IWMG in high-risk myeloma patients


	MRD/ Flow	MRD/ Flow
	negative	positive
Complete remission	8 (50%)	8 (50%)
PR or VGPR	5 (38%)	8 (62%)

Figure S1. Overall survival of high-risk myeloma patients who were MRD negative by remission status (CR or NOT CR [PR/VGPR]). Median OS was not reached in either group.




OS of high OS lofnhyghonriakpatiendesnalpatiendesnalpatiendesnalpatiendesnalpatiendesnalpatiendesnalpatiendesna

Figure S2. Progression free survival of high-risk myeloma patients who were MRD negative by remission status (CR and NOT CR [PR/VGPR]). Median PFS was not reached and 23 months in CR and not CR patients, respectively.



PFS of high-risk myeloma patients who achieved MRD/flow negativity by CR status PFS of high-risk patients achieved MRD negative

Figure S3. Progression free survival of high-risk myeloma patients who achieved CR by MRD status. Median PFS was not reached in either group



PFS of high-risk myeloma patients who achieved CR by MRD/status PFS of high-risk patients achieved CR

Figure S4. Overall survival of high-risk myeloma patients who achieved CR by MRD status. Median OS was not reached in either group.




Figure S5. Progression free survival of high-risk myeloma patients who did not achieve a CR by flow status. Median PFS was 23 and 30 months in flow positive and negative patients, respectively.





Figure S6. Overall survival of high-risk myeloma patients who did not achieve CR by flow status. Median OS was not reached in either group.






Figure S7. Progression frees survival in high-risk myeloma patients by CR and MRD status.




Figure S8. Overall survival in high-risk myeloma patients by CR and MRD status.

